KRT88P and non-Hodgkin lymphoma: This multicenter, randomized, placebo-controlled trial assessed the efficacy of preemptive antiviral therapy in HBsAg-negative, anti–HBc-positive patients receiving rituximab-based chemotherapy for non-Hodgkin lymphoma (NHL).